fashion -WSS

fashion

author：hotspot 2025-09-30 01:19:31 - browse：135

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Emergent cuts jobs, executive role in business shake

WSS

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Weight loss drugs aren’t covered by Obamacare. That may change

Police still searching for prisoner who escaped from NYC hospital

Secretariat’s lessons for human medicine

Ukraine seeks to reclaim its role as a hub for clinical trials

How to use technology to prevent future drug shortages

focus

fashion

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

MD Anderson's Padmanee Sharma responds to research credit suit

Novavax promises a turnaround & Lilly roils the obesity market

FDA warns medical device makers about rise in fabricated data

DIEP, the 'gold standard' of breast reconstruction, is under threat

Naloxone nonprofit donates 200,000 doses after FDA approval

Malaria cases in Florida and Texas: Here’s what you need to know

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

New air purifier tech could be key to improving indoor air quality

Congress may force more Covid

entertainment

New CMS data security rules will hurt Medicare, Medicaid research

In same hospitals, Black patients receive fewer opioids than white patients

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Anavex keeps shifting the goalposts in its clinical trials

Weight loss drugs aren’t covered by Obamacare. That may change

knowledge

Wikipedia

hotspot

hotspot